The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Narazaciclib’s kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models.
 
Petros Kechagioglou
Research Funding - Onconova Therapeutics
 
Camille Dupont
Research Funding - Onconova Therapeutics
 
Hajime Yurugi
No Relationships to Disclose
 
Ute Distler
No Relationships to Disclose
 
Stefan Tenzer
Patents, Royalties, Other Intellectual Property - University Medical Center Mainz
 
Alexey Chernobrovkin
Employment - Pelago Bioscience AB
 
Kristina Riegel
Consulting or Advisory Role - Merz Pharma
 
Stephen Cosenza
Employment - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
Consulting or Advisory Role - Onconova Therapeutics
Patents, Royalties, Other Intellectual Property - Onconova Therapeutics
 
Steven M. Fruchtman
Employment - Onconova Therapeutics
Leadership - Onconova Therapeutics
Stock and Other Ownership Interests - Onconova Therapeutics
Patents, Royalties, Other Intellectual Property - Onconova Therapeutics
Travel, Accommodations, Expenses - Onconova Therapeutics
 
Krishnaraj Rajalingam
Leadership - KHR Biotec
Stock and Other Ownership Interests - KHR Biotec
Consulting or Advisory Role - BioNTech; Indivumed; KHR Biotec; Onconova Therapeutics
Patents, Royalties, Other Intellectual Property - Johannes Gutenberg University Medical Centre Mainz